Out of the 14 identified subtypes of the Ehlers-Danlos syndromes, hypermobile EDS (hEDS) is the most prevalent type and is the only one for which we currently do not have a genetic marker. Our moonshot is a clinical research study with the goal of finding the underlying genetics and gene expression/s of hEDS. The research will start by enrolling 1000 study participants with a confirmed diagnosis of hEDS based on the 2017 criteria.
This study has Institutional Review Board oversight and approval by the Genetic Alliance (IORG0003358) IRB (IRB00003999). Genetic Alliance Federal Wide Assurance number is: FWA00017292. More information can be found on this IRB by putting Genetic Alliance in the NAME search field on the Office of Human Research Protections website.
Protocol EDS002 has been approved by the Genetic Alliance IRB (Federal registration number IORG0003358)
Individuals who may meet the hEDS 2017 criteria should first complete the surveys in the Global Registry. Based on those responses, we will invite candidates who are eligible, and after obtaining informed consent, we will arrange for a blood sample to be taken either at your home or close to where you live for genetic tests, including whole-genome sequencing. Fasting is not required. These tests will help our researchers in their efforts to identify the possible genetic cause(s) of hEDS.
We are no longer doing in-person enrollment events in 2020 and hope to conclude the enrollment through online screening. However, we may need to do some in-person events in 2021 or later when travel is no longer restricted and if we have not reached our target number of 1000 samples.
To be considered for the study, you must first have a diagnosis of hEDS given by a doctor, then enroll in the EDS global registry, complete the personal and family history surveys, and upload the necessary documents to show the diagnosis.
Typically, this will be the record from the initial visit where your provider made the diagnosis. A document or record simply stating you meet the requirements will not be sufficient; the specific elements required by the 2017 guidelines must be included. Some examples of documents would be; a letter confirming the diagnosis, or a completed hEDS 2017 diagnostic checklist.
If you do not have the full record from the visit when your doctor first established the diagnosis, you should request it from your doctor. However, if that visit was before 2017, it is unlikely the record will contain the required itemized information. After you obtain the record establishing your diagnosis under the 2017 criteria, you should upload it to the EDS and HSD Global Registry.
You can find the registry here: ehlers-danlos.com/eds-global-registry/. If accepted, we will contact you to obtain consent and arrange the blood draw.
There is no cost to you to participate in the study itself.
Currently, we are able to arrange blood draws from all areas of the world except Central and South America. Upon invitation, we will work with each candidate to ensure we have adequate coverage to complete the blood draw with one of our providers. We are working on finding providers for the Central and South America regions to enable worldwide access to this study.
Your travel expenses will not be covered. Costs to consider may include travel, lodging, food, and conference registration (if applicable).
Currently, all enrolment is virtual, you will need to upload all the necessary documents onto the registry and we will contact you if you meet the criteria so that we can arrange the blood draw. If there are any in-person events in the future we will let everyone know.
If you have already uploaded the necessary documents and completed all required surveys on our Global Registry, then you don’t need to do anything. We will review the information you uploaded and determine if those documents contain the information required to meet the 2017 criteria. For most people invited to screening events, the uploaded documents did not have the necessary information. If you were invited to a screening event, we will let you know before the end of 2020 whether your uploaded documents meet the requirements.
Your consent should take approximately 15minutes and your blood draw is around 15-30 minutes.
As physical distance is impossible during the blood draw process, the following protective measures will be in place:
- All examiners will be required to wear facial protection that covers the eyes, nose, and mouth
- All examiners will be required to wear gloves
The age limit is 16 years to 99 years old.
Yes. The EDS Global Registry data is securely stored on the Platform for Engaging Everyone Responsibly (PEER platform) and held in an environment that is compliant with rules related to privacy and security of information, including those of European General Data Protection Regulation (GDPR). To learn more about the PEER platform and about the EDS Global Registry please refer to the frequently asked questions (FAQ) listed at the bottom of the EDS Global registry page.
Yes. The blood sample will be used for whole genome sequencing and the results will remain private and confidential. The sequencing data will be analyzed by researchers to look for the genetic causes of hEDS. Researchers viewing these samples and data will not have access to identifying information.
It is important to remember that this is a research study and not a diagnostic test. However, if the study identifies a genetic variant that appears to be responsible for hEDS, we will notify participants with that genetic variant and provide further explanatory information.
Fill out the following fields, click submit, and someone from the research team will get in touch with you.
Participants in the HEDGE study have consented to their blood samples being tested for whole genome sequencing. The results of these tests are private and confidential. The DNA is not sold to a third party. Sequencing data will be analyzed by researchers to look for the genetic causes of hEDS. Researchers viewing the data will not have access to identifying information.
HEDGE is fully funded by gifts from two anonymous private donors, whose families have been impacted by hypermobile EDS. None of the individuals funding this study have any commercial interest, ownership, or rights to any of the data from this study.